Nurtec ODT (rimegepant ODT) / Pfizer - LARVOL DELTA

A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention. (PubMed, J Headache Pain) - P4 | "Rimegepant 75 mg QD for up to 24 weeks had a favorable safety profile for preventive treatment of EM."

Journal • P4 data • CNS Disorders • Dyslipidemia • Hypertriglyceridemia • Infectious Disease • Migraine • Novel Coronavirus Disease • Pain

Gepants: targeting the CGRP pathway for migraine relief. (PubMed, Front Pharmacol) - "Several new agents (atogepant, ubrogepant, rimegepant, and zavegepant) expand therapeutic options beyond traditional triptans and monoclonal antibodies. Gepants represent a valuable advancement in migraine therapy, offering effective acute and preventive options with favorable tolerability, particularly for patients who cannot use triptans or who have cardiovascular risk factors. Ongoing studies will clarify long-term safety, real-world effectiveness, and potential roles in combination or sequential therapy."

Journal • Review • Cardiovascular • CNS Disorders • Fatigue • Migraine • Pain

CORRELATE-UK: Consistency of Response With Rimegepant in Acute Treatment of Migraine (clinicaltrials.gov) - P=N/A | N=250 | Active, not recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Migraine • Pain

Migraine treatment outcomes with rimegepant in rimegepant-naive patients: A real-world, multi-center, prospective, observational study (EHF-EHC 2025) - P | "A total of 6 (0.28%) adverse events (AEs) were reported during rimegepant treatment, with no serious AEs. Subgroup analysis demonstrated that rimegepant is effective and well-tolerated for acute migraine therapy in rimegepant-naive patients."

Clinical • Observational data • Real-world • Real-world evidence • CNS Disorders • Migraine • Pain

Who benefits from acute treatment with rimegepant? Aligning goals & guidelines with a patient-centred approach (EHF-EHC 2025) - "Sponsored by Pfizer Inc."

Clinical • Pain

Time course of rimegepant effect for acute treatment of migraine in adults unsuitable for triptans: Exploratory endpoints from a phase 4 randomized double-blind placebo-controlled study (EHF-EHC 2025) - P4 | "Differences (95% CI) at 48 hours were 31.2% (23.5%, 39.0%; P <0.0001) for pain relief, 33.4% (25.9%, 40.9%; P <0.0001) for pain freedom, 34.1% (25.8%, 42.5%; P <0.0001) for return to normal function, and 23.2% (15.5%, 31.0%; P <0.0001) for MBS freedom. Improvements in migraine symptoms occurred within 1–2 hours of treatment with rimegepant and were sustained over 48 hours in adults unsuitable for triptans."

Clinical • P4 data • CNS Disorders • Migraine • Pain

What is the consistency of response to rimegepant at a group level in the acute treatment of migraine in UK adult patients? Protocol for a real-world, patient-centred study (EHF-EHC 2025) - P | "Results will be shared once available. CORRELATE-UK will assess real-world effectiveness of rimegepant for acute migraine treatment across multiple attacks over 12 weeks in a UK population, including in those on preventive therapy and with chronic migraine."

Clinical • Real-world • Real-world evidence • CNS Disorders • Migraine • Pain

New trends in migraine management: Transcending the traditional divide between acute and preventive treatments (EHF-EHC 2025) - "Acute medications like lasmiditan and rimegepant not only relieve symptoms quickly but also lower attack frequency and disease impact over time. Clinicians should understand that acute and preventive treatments are linked goals to improve management and prevent progression. Personalized plans are needed to enhance both treatments and lessen the overall impact on patients."

CNS Disorders • Migraine • Pain

Use of gepants in the acute treatment and bout modulation of cluster headache: A retrospective case series (EHF-EHC 2025) - "Notably, no traditional preventive therapies (e.g., verapamil, corticosteroids) were used during the reported bout Retrospective case series of six CH patients who used gepants during a recent cluster bout...Rimegepant 70 mg (every other day, 16–28 days) was used by four patients; two used atogepant 60 mg/day (28 days)...Their efficacy in chronic CH remains uncertain. These preliminary findings warrant confirmation in prospective, controlled studies"

Retrospective data • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Migraine • Pain

Rimegepant for the prevention of episodic migraine in adults with prior inadequate response to oral preventatives: Results from a 12-week open-label extension phase of a randomized, placebo-controlled trial (EHF-EHC 2025) - P4 | "Rimegepant 75 mg EOD is well tolerated and reduces overall disease burden when taken for the prevention of migraine in participants with a documented history of prior inadequate response to OPMs. NCT05518123"

Clinical • CNS Disorders • Diabetes • Hematological Disorders • Hypoglycemia • Migraine • Pain • Thrombocytopenia

Pfizer Inc. – Preventive treatment: Oral CGRP targeting therapies for first-line prevention of migraine: meeting patient needs with Rimegepant (EHF-EHC 2025) - "Sponsored by Pfizer Inc."

Clinical • CNS Disorders • Migraine • Pain

Case report: Retinal involvement in recurrent painful ophthalmoplegic neuropathy with reversible color vision impairment (EHF-EHC 2025) - "Acute treatments (rizatriptan, ibuprofen, loxoprofen, rimegepant) failed; only indomethacin provided relief. Interictal IV nitroglycerin failed to induce migraine-like headache...By inhibiting cyclooxygenase (COX), indomethacin suppresses prostaglandin synthesis, reducing prostaglandin-mediated sensitization of trigeminovascular afferents, suggesting trigeminovascular afferent sensitization in RPON. Furthermore, RPON pathophysiology may involve retinal neuronal networks beyond the oculomotor nerve, supported by PERG amplitude changes implicating inner retinal layer pathology, indicating pathogenesis distinct from classical cranial neuropathies."

Case report • Clinical • CNS Disorders • Migraine • Neuralgia • Ophthalmology • Pain

Four‑year real‑world efficacy and tolerability of anti‑CGRP therapies in a tertiary headache centre in England (EHF-EHC 2025) - "A total of 548 treatments were initiated in 415 patients (rimegepant: n=57; atogepant: n=60; erenumab: n=283; fremanezumab: n=136; galcanezumab: n=12). Atogepant was associated with the most adverse effects, with constipation, dizziness, and "brain fog" reported. Fremanezumab was associated with a higher treatment success rate than erenumab, rimegepant, and atogepant in our cohort."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Migraine • Pain

Exploring management in prevention of episodic migraine with rimegepant (EHF-EHC 2025) - "Sponsored by Pfizer Inc."

CNS Disorders • Migraine • Pain

Reasons for discontinuing triptans among current users of rimegepant for the acute treatment of migraine in the CONFIDENCE study (EHF-EHC 2025) - P | "The three other most common reasons were more frequently reported in participants with more lapsed triptans. NCT06467370"

CNS Disorders • Migraine • Pain

Real-world analysis of headache recurrence and next-day medication use following acute migraine therapy: Insights from 3 million attacks in the Migrebot e-Diary (EHF-EHC 2025) - "Gepants demonstrated the lowest rates of headache recurrence and next-day medication use (rimegepant 25.64%/16.8%, ubrogepant 30.82%/22.22% respectively) Table 1. The consistency of results across years strengthens the validity of these findings. Digital diary data provides crucial insights into long-term treatment performance, directly informing clinical practice for improved migraine management."

Clinical • Real-world • Real-world evidence • CNS Disorders • Migraine • Pain

Changes in acute treatment effectiveness in migraine patients switching from standard of care to rimegepant: Findings from a real-world study (EHF-EHC 2025) - P | "Significantly more patients reported satisfaction (extremely/very/somewhat) with pain relief and RNF after taking rimegepant than those with SOC-treated RMAs (p < 0.0001) (Table 1) . In this real-world study, migraineurs switching from SOC to rimegepant reported more effective pain relief, more rapid relief of pain and associated symptoms, and greater patient satisfaction with pain relief and RNF."

Clinical • Real-world • Real-world evidence • CNS Disorders • Migraine • Pain

The efficacy of gepants in the prophylactic management of migraine: A systematic review (EHF-EHC 2025) - "PubMed and BVS were searched through March 2025 for randomized controlled trials (RCTs) evaluating rimegepant or atogepant for migraine prevention. Their favorable safety profile and ease of use make them a valuable alternative to existing therapies. Further long-term, head-to-head studies are needed to confirm their sustained efficacy and comparative effectiveness."

Clinical • Review • CNS Disorders • Migraine • Pain

Treatment switching after first Anti-CGRP MAb failure in migraine: Gepants or another MAb? (EHF-EHC 2025) - "This retrospective observational study included patients from a tertiary Headache Unit who switched to a gepant (atogepant or rimegepant) or to a second mAb following the failure of a first mAb between May 2024 and March 2025. Switching to a gepant or another mAb after failure of a first mAb shows similar overall outcomes. However, a trend towards a higher clinical response and better tolerability was observed in the gepant group, warranting further confirmation in prospective comparative studies."

CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Migraine • Pain

Efficacy of rimegepant in treating acute vertigo attacks in vestibular migraine: A retrospective open-label study (EHF-EHC 2025) - "These findings suggest that RIM may be effective in reducing vertigo and associated symptoms in patients with VM or pVM. However, confirmation through large-scale, randomized controlled trials is warranted."

Retrospective data • CNS Disorders • Migraine • Otorhinolaryngology • Pain • Vertigo

Sex differences in the response to rimegepant for the treatment of acute migraine attacks – Insights from the multicenter GAINER study (EHF-EHC 2025) - "Nevertheless, the drug was effective in both sexes. Preclinical and clinical studies are needed to elucidate the possible mechanisms determining a sex difference in response to rimegepant."

Clinical • CNS Disorders • Migraine • Pain • CALCRL

Patient-reported outcomes through 12-weeks of double-blind rimegepant treatment for the prevention of episodic migraine in adults with prior inadequate response to oral preventatives (EHF-EHC 2025) - P4 | "Rimegepant 75 mg ODT EOD is associated with reductions in disease burden when taken for the prevention of EM for 12 weeks in participants with documented prior inadequate response to 2-4 categories of non-migraine specific OPM. NCT05518123"

Clinical • Patient reported outcomes • CNS Disorders • Migraine • Pain

Pfizer Inc. – Acute treatment: Optimizing your patients’ acute treatment journey: harnessing real-world evidence on Rimegepant (EHF-EHC 2025) - "Sponsored by Pfizer Inc."

Clinical • HEOR • Real-world • Real-world evidence • Pain

Safety and effectiveness of rimegepant for acute treatment of migraine in adults unsuitable for triptan use: Results from a 12-week open-label extension phase (EHF-EHC 2025) - P4 | "Mean (SD) change in MMDs was −2.8 (3.3) days ( Figure 1 ), and 38.9% of participants achieved ≥50% reduction ( Figure 2 ). In triptan-unsuitable adults, RIM 75 mg ODT PRN for up to 12 weeks demonstrated favorable safety, stable population-level effects across repeated attacks, and fewer MMDs."

Clinical • CNS Disorders • Migraine • Pain

Failure of CGRP inhibition as a treatment for complex regional pain syndrome (EHF-EHC 2025) - "She was started on galcanezumab (anti-CGRP monoclonal antibody), resulting in a rapid and sustained reduction in migraine frequency (from 16 to 4 days/month) and severity, with significant improvement in quality of life. Rimegepant (a CGRP receptor antagonist) was also effective for acute attacks...While migraine predominantly involves CGRP-mediated trigeminovascular pathways, CRPS may involve more complex and multifactorial mechanisms, including central sensitization, neurogenic inflammation, and autonomic dysfunction. This example underscores the importance of a differentiated approach to chronic pain conditions, even in the presence of shared biomarkers."

CNS Disorders • Inflammation • Migraine • Musculoskeletal Pain • Pain